A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Condition: HIV-1 Infection Interventions: Drug: DOR/ISL; Drug: BIC/FTC/TAF; Drug: Placebo to BIC/FTC/TAF; Drug: Placebo to DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
Condition: HIV-1 Infection Interventions: Drug: ART; Drug: DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Condition: HIV-1 Infection Interventions: Drug: DOR/ISL; Drug: BIC/FTC/TAF; Drug: Placebo to BIC/FTC/TAF; Drug: Placebo to DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
Condition: HIV-1 Infection Interventions: Drug: ART; Drug: DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Condition: HIV-1 Infection Interventions: Drug: DOR/ISL; Drug: BIC/FTC/TAF; Drug: Placebo to BIC/FTC/TAF; Drug: Placebo to DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
Condition: HIV-1 Infection Interventions: Drug: ART; Drug: DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Condition: HIV-1 Infection Interventions: Drug: DOR/ISL; Drug: BIC/FTC/TAF; Drug: Placebo to BIC/FTC/TAF; Drug: Placebo to DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
Condition: HIV-1 Infection Interventions: Drug: ART; Drug: DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Condition: HIV-1 Infection Interventions: Drug: DOR/ISL; Drug: BIC/FTC/TAF; Drug: Placebo to BIC/FTC/TAF; Drug: Placebo to DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
Condition: HIV-1 Infection Interventions: Drug: ART; Drug: DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Condition: HIV-1 Infection Interventions: Drug: DOR/ISL; Drug: BIC/FTC/TAF; Drug: Placebo to BIC/FTC/TAF; Drug: Placebo to DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
Conditions: COVID-19; Chronic Kidney Disease stage4; Chronc Kidney Disease Stage 5 Intervention: Drug: Nirmatrelvir/ritonavir Sponsor: Chinese University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2022 Category: Research Source Type: clinical trials
